Abbott Q3 sales rise 14.5% to $13.0 billion; GAAP EPS falls to $0.53
Abbott reported third-quarter 2026 results on October 21, 2026, with net sales up 14.5% to $13.0 billion, aided by the Exact Sciences acquisition completed March 23, 2026. GAAP diluted EPS fell 43.6% to $0.53 after specified items, including about $670 million of legal settlements and $841 million of intangible amortization, while adjusted diluted EPS rose 9.2% to $1.42. The company tightened its full-year 2026 adjusted EPS guidance to $5.50 to $5.55, reaffirming the midpoint, which matters to shareholders because reported profit fell sharply even as sales and adjusted earnings grew.
Key points
- Third-quarter net sales were $13,013 million, up 14.5% reported and 7.0% on a comparable basis.
- GAAP diluted EPS was $0.53, down from $0.94 a year earlier; adjusted diluted EPS was $1.42, up from $1.30.
- Specified items included about $670 million in legal settlements and $841 million in intangible amortization.
- Full-year 2026 adjusted diluted EPS guidance was narrowed to $5.50 to $5.55, with the midpoint reaffirmed; projected comparable sales growth is approximately 6.0%.
The filing
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.